Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pegasus Biologics Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.pegasusbio.com

Latest From Pegasus Biologics Inc.

Tissue Repair Start-Ups Fill Orthopedics' Gaps

Technologies for total joint repair, the backbone of the orthopedics industry, have occupied most of the development resources of orthopedic companies, but there are gaps in the continuum of care when it comes to tendon and ligament repair. ACL reconstruction and rotator cuff repair thus are attractive niches for start-ups, worth anywhere from $500 million to $1 billion. Soft tissue repair expertise is outside the core skill-sets of big ortho, but those companies have been willing to partner and acquire smaller innovative players. Today, the opportunity is even more attractive; sports medicine--the realm of soft tissue repair--enjoys an economic resiliency not seen in total joint replacement. Ligament tears more closely resemble trauma applications, which must be treated as soon as possible.
Medical Device

Ablation Frontiers: Making AF Ablation Simple and Universal

Despite widespread and increasing prevalence, atrial fibrillation has frustrated clinicians, device companies, and investors, resulting in only a small number of doctors treating a small number of patients. Ablation Frontiers believes its system will finally enable many more doctors to treat all types of AF patients because it is developing products and procedures that are simpler for doctors to use and perform, finally providing a broad-based solution to this rapidly growing market.
Medical Device

Deals Update (06/2007)

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Medical Device

Joint Resurfacing: Boom or Bust?

One of the hottest topics at the 2007 AAOS was the the trend toward resurfacing rather than completely replacing joints damaged by arthritis and other causes. There are a variety of metallic, synthetic and biologic methods used in hip, knee, shoulder and extremity joint resurfacing, many designed for younger patients who wish to remain active and avoid total joint replacement.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Michael Will, Pres. & CEO
    Tom Sander, VP, Research & Bus. Dev.
    Rob Cripe, VP, Mktg. & Product Dev.
    James Jungwirth, VP, Fin. & Admin.
  • Contact Info
  • Pegasus Biologics Inc.
    Phone: (949) 502-3240
    6 Jenner
    Ste. 150
    Irvine, CA 92618
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register